Receptor-selective variants of human vascular endothelial growth factor - Generation and characterization

被引:78
作者
Li, B
Fuh, G
Meng, G
Xin, XH
Gerritsen, ME
Cunningham, B
de Vos, AM
机构
[1] Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Bioanalyt Technol, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Cardiovasc Res, San Francisco, CA 94080 USA
关键词
D O I
10.1074/jbc.M002015200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vascular endothelial growth factor (VEGF) is a pleiotropic factor that exerts a multitude of biological effects through its interaction with two receptor tyrosine kinases, fms-like tyrosine kinase (Flt-1) or VEGF receptor 1 and kinase insert domain-containing receptor (KDR) or VEGF receptor 2. Whereas it is commonly accepted that KDR is responsible for the proliferative activities of VEGF, considerable controversy and uncertainty exist about the role of the individual receptors in eliciting many of the other effects. Based on a comprehensive mutational analysis of the receptor-binding site of VEGF, an Flt-1-selective variant was created containing four substitutions from the wild-type protein. This variant bound with wild-type affinity to Flt-1, was at least 470-fold reduced in binding to KDR, and had no activity in cell-based assays measuring autophosphorylation of KDR or proliferation of primary human vascular endothelial cells. Using a competitive phage display strategy, two KDR-selective variants were discovered with three and four changes from wild-type, respectively. Both variants had approximately wild-type affinity for KDR, were about 2000-fold reduced in binding to Flt-1, and showed activity comparable with the wild-type protein in KDR autophosphorylation and endothelial cell proliferation assays. These variants will serve as useful reagents in elucidating the roles of Flt-1 and KDR.
引用
收藏
页码:29823 / 29828
页数:6
相关论文
共 37 条
[1]  
Bauters C, 1997, CLIN CARDIOL, V20, P52
[2]   Heterodimers of placenta growth factor vascular endothelial growth factor - Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR [J].
Cao, YH ;
Chen, H ;
Zhou, L ;
Chiang, MK ;
AnandApte, B ;
Weatherbee, JA ;
Wang, YD ;
Fang, FY ;
Flanagan, JG ;
Tsang, MLS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (06) :3154-3162
[3]   HUMAN GROWTH-HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR - CRYSTAL-STRUCTURE OF THE COMPLEX [J].
DEVOS, AM ;
ULTSCH, M ;
KOSSIAKOFF, AA .
SCIENCE, 1992, 255 (5042) :306-312
[4]   The biology of vascular endothelial growth factor [J].
Ferrara, N ;
DavisSmyth, T .
ENDOCRINE REVIEWS, 1997, 18 (01) :4-25
[5]   Role of vascular endothelial growth factor in the regulation of angiogenesis [J].
Ferrara, N .
KIDNEY INTERNATIONAL, 1999, 56 (03) :794-814
[6]   Clinical applications of angiogenic growth factors and their inhibitors [J].
Ferrara, N ;
Alitalo, K .
NATURE MEDICINE, 1999, 5 (12) :1359-1364
[7]   ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31
[8]   ROLE OF THE FLT-1 RECEPTOR TYROSINE KINASE IN REGULATING THE ASSEMBLY OF VASCULAR ENDOTHELIUM [J].
FONG, GH ;
ROSSANT, J ;
GERTSENSTEIN, M ;
BREITMAN, ML .
NATURE, 1995, 376 (6535) :66-70
[9]   Growth factors in age-related macular degeneration: Pathogenic and therapeutic implications [J].
Frank, RN .
OPHTHALMIC RESEARCH, 1997, 29 (05) :341-353
[10]   Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor [J].
Fuh, G ;
Li, B ;
Crowley, C ;
Cunningham, B ;
Wells, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (18) :11197-11204